Cargando…

STAT5 fits the RISK profile for cardioprotection

How wonderful would it be if there were a simple, cheap, safe, non-invasive treatment that could be administered to a patient to protect their organs from ischemia and reperfusion? Such a treatment might be used to protect the organs during temporary loss of blood flow, as occurs for example during...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Sean M., Yellon, Derek M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670296/
https://www.ncbi.nlm.nih.gov/pubmed/24058753
http://dx.doi.org/10.4161/jkst.20072
_version_ 1782271839647563776
author Davidson, Sean M.
Yellon, Derek M.
author_facet Davidson, Sean M.
Yellon, Derek M.
author_sort Davidson, Sean M.
collection PubMed
description How wonderful would it be if there were a simple, cheap, safe, non-invasive treatment that could be administered to a patient to protect their organs from ischemia and reperfusion? Such a treatment might be used to protect the organs during temporary loss of blood flow, as occurs for example during a heart attack or stroke. As unlikely as this may sound, such a treatment has indeed been discovered, although research into the mechanism is only just beginning. A recent paper by Heusch et al. in Circulation Research has taken the first step in this direction, as explained below.
format Online
Article
Text
id pubmed-3670296
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36702962013-09-19 STAT5 fits the RISK profile for cardioprotection Davidson, Sean M. Yellon, Derek M. JAKSTAT Commentary How wonderful would it be if there were a simple, cheap, safe, non-invasive treatment that could be administered to a patient to protect their organs from ischemia and reperfusion? Such a treatment might be used to protect the organs during temporary loss of blood flow, as occurs for example during a heart attack or stroke. As unlikely as this may sound, such a treatment has indeed been discovered, although research into the mechanism is only just beginning. A recent paper by Heusch et al. in Circulation Research has taken the first step in this direction, as explained below. Landes Bioscience 2012-04-01 /pmc/articles/PMC3670296/ /pubmed/24058753 http://dx.doi.org/10.4161/jkst.20072 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Commentary
Davidson, Sean M.
Yellon, Derek M.
STAT5 fits the RISK profile for cardioprotection
title STAT5 fits the RISK profile for cardioprotection
title_full STAT5 fits the RISK profile for cardioprotection
title_fullStr STAT5 fits the RISK profile for cardioprotection
title_full_unstemmed STAT5 fits the RISK profile for cardioprotection
title_short STAT5 fits the RISK profile for cardioprotection
title_sort stat5 fits the risk profile for cardioprotection
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670296/
https://www.ncbi.nlm.nih.gov/pubmed/24058753
http://dx.doi.org/10.4161/jkst.20072
work_keys_str_mv AT davidsonseanm stat5fitstheriskprofileforcardioprotection
AT yellonderekm stat5fitstheriskprofileforcardioprotection